General Admission [X] Admit to inpatient acute rehab Diagnosis: Admitting Physician: Bed request comments: Certification: I certify that based on my best clinical judgement and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. Other **Code Status** [] Full code Code Status decision reached by: [] DNR [] DNR (Do Not Resuscitate) Does patient have decision-making capacity? [] Consult to Palliative Care Service Priority: Reason for Consult? Order? Name of referring provider: Enter call back number: [] Consult to Social Work Reason for Consult: Does patient have decision-making capacity? [] Modified Code Modified Code restrictions: **Treatment Restrictions** Treatment Restriction decision reached by: Specify Treatment Restrictions: Other Isolation [] Airborne isolation status **Details** Contact isolation status **Details** [] Droplet isolation status **Details** [] Enteric isolation status Details Other **Precautions** Aspiration precautions **Details** [] Fall precautions Increased observation level needed: Latex precautions Details Increased observation level needed: Seizure precautions [] Sternal precaution [] Range of motion precaution Routine, Until discontinued, Starting S Spinal - Cervical orthosis precautions **Details** Spinal thoraco-lumbar precautions **Details** Hip precautions Precaution: [] Other **Common Present on Admission Diagnosis** [] Acidosis **Details** [] Acute Post-Hemorrhagic Anemia Details [] Acute Renal Failure Details Acute Respiratory Failure **Details** Acute Thromboembolism of Deep Veins of Lower **Details** Extremities Anemia Details

Rehabilitation Program Admission [1758]

| [1] Destauration | Datalla |
|---|--|
| [] Bacteremia | Details Details |
| Bipolar disorder, unspecified | Details Details |
| [] Cardiac Arrest | Details Details |
| [] Cardiac Dysrhythmia | Details Details |
| [] Cardiogenic Shock | Details |
| Decubitus Ulcer | Details |
| Dementia in Conditions Classified Elsewhere | Details |
| Disorder of Liver | Details |
| [] Electrolyte and Fluid Disorder | Details |
| [] Intestinal Infection due to Clostridium Difficile | Details |
| Methicillin Resistant Staphylococcus Aureus Infection | Details |
| [] Obstructive Chronic Bronchitis with Exacerbation | Details |
| [] Other Alteration of Consciousness | Details |
| [] Other and Unspecified Coagulation Defects | Details |
| [] Other Pulmonary Embolism and Infarction | Details |
| [] Phlebitis and Thrombophlebitis | Details |
| [] Protein-calorie Malnutrition | Details |
| [] Psychosis, unspecified psychosis type | Details |
| [] Schizophrenia Disorder | Details |
| [] Sepsis | Details |
| [] Septic Shock | Details |
| [] Septicemia | Details |
| [] Type II or Unspecified Type Diabetes Mellitus with | Details |
| Mention of Complication, Not Stated as Uncontrolled | D : " |
| [] Urinary Tract Infection, Site Not Specified | Details |
| [] Other | |
| | |
| Nursing | |
| | |
| Vitals Signs | |
| Vitals Signs | |
| Vitals Signs [] Vital signs - T/P/R/BP | Routine, Every 8 hours |
| | Routine, Every 8 hours Inform MD if: |
| | Inform MD if: |
| | |
| | Inform MD if:Heart Rate greater than 100 bpm or less than 55 bpm, or |
| | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 |
| [] Vital signs - T/P/R/BP | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg |
| | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily |
| [] Vital signs - T/P/R/BP | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: |
| [] Vital signs - T/P/R/BP | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% |
| Vital signs - T/P/R/BP | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: |
| Vital signs - T/P/R/BP | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% |
| Vital signs - T/P/R/BP Pulse oximetry Neurovascular checks Other | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% |
| Vital signs - T/P/R/BP Pulse oximetry Neurovascular checks Other Activity Activity Other Activity | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours |
| Vital signs - T/P/R/BP Pulse oximetry Neurovascular checks Other | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, 3 times daily Specify: with assistance |
| Vital signs - T/P/R/BP Pulse oximetry Neurovascular checks Other Activity Activity Other Activity | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, 3 times daily Specify: with assistance Routine, Until discontinued, Starting S |
| Vital signs - T/P/R/BP | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, 3 times daily Specify: with assistance Routine, Until discontinued, Starting S Specify: Up with assistance |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Specify: Up with assistance |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance [] Up with assistance | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Position: |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance [] Up with assistance [] Patient position: | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Position: Additional instructions: |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance [] Up with assistance | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Position: Additional instructions: Routine, Until discontinued, Starting S |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance [] Up with assistance [] Patient position: | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Position: Additional instructions: Routine, Until discontinued, Starting S Weight Bearing Status: |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance [] Up with assistance [] Patient position: [] Weight bearing | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Position: Additional instructions: Routine, Until discontinued, Starting S Weight Bearing Status: Extremity: |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance [] Up with assistance [] Patient position: | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Position: Additional instructions: Routine, Until discontinued, Starting S Weight Bearing Status: Extremity: Routine, Until discontinued, Starting S |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance [] Up with assistance [] Patient position: [] Weight bearing | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Position: Additional instructions: Routine, Until discontinued, Starting S Weight Bearing Status: Extremity: Routine, Until discontinued, Starting S Left/Right: |
| [] Vital signs - T/P/R/BP [] Pulse oximetry [] Neurovascular checks [] Other Activity [] Ambulate with assistance [] Up with assistance [] Patient position: [] Weight bearing | Inform MD if: -Heart Rate greater than 100 bpm or less than 55 bpm, or -SBP greater than 170 mm/Hg or DBP greater than 100 mm/Hg Routine, Daily Current FIO2 or Room Air: Inform MD if O2 saturations is less than 90% Routine, Every 8 hours Routine, Every 8 hours Routine, Until discontinued, Starting S Specify: Up with assistance Routine, Until discontinued, Starting S Position: Additional instructions: Routine, Until discontinued, Starting S Weight Bearing Status: Extremity: Routine, Until discontinued, Starting S |

| [] Cervical collar | Routine, Once Type of Collar to Apply: |
|--|---|
| | Special Instructions: |
|] Other | |
| General Nursing | |
| [] Weigh patient | Routine, Once For 1 Occurrences On admission |
| [] Weigh patient | Routine, Weekly |
| 11 Daily weights | Every Monday Routine, Daily |
| Daily weights 1:1 patient | Routine, Daily Routine, Continuous |
| Bed and chair alarm on | Routine, Continuous Routine, Until discontinued, Starting S |
| Intake and output | Routine, Every 8 hours |
| Strict intake and output | Routine, Every 6 Hours |
|] Bedside glucose | Routine, 4 times daily before meals and at bedtime |
| <u> </u> | Routine, Once |
| Abdominal binder | Waking hours only? |
| | Nurse to schedule? |
| | Special Instructions: |
| Gastric tube maintenance | Routine, Until discontinued, Starting S |
| 1 Gasars take maintenance | Drainage: |
| | Intervention: |
| 1 Tube site care | Routine, As needed |
| | Use normal saline with soap every shift as needed |
|] Skin care | Routine, As needed |
| • | Hand and foot care PRN for dry skin |
|] Measure right thigh circumference | Routine, Once |
| | On admission, weekly and PRN |
|] Measure right calf circumference | Routine, Once |
| | On admission, weekly and PRN |
|] Measure left thigh circumference | Routine, Once |
| | On admission, weekly and PRN |
|] Measure left calf circumference | Routine, Once |
| | On admission, weekly and PRN |
|] Place antiembolic stockings | Routine, Once |
|] Other | |
| Bladder Management | |
|] Insert and maintain Foley | |
| [] Insert Foley catheter | Routine, Once |
| | Type: |
| | Size: |
| II. Fals. Oath to Oas | Urinometer needed: |
| [] Foley Catheter Care | Routine, Until discontinued, Starting S |
| | Orders: Maintain |
| 1. For nationto without a falou | Change open system foley catheter every 2 weeks |
| For patients without a foley | Pouting Every 4 hours |
| Straight cath | Routine, Every 4 hours |
| [] Bladder scan | Routine, Every 4 hours For 3 Occurrences Post-void residual: Notify MD if PVR is greater than 250 r |
| | or random bladder scan greater than 450 ml |
| Timed voids | Routine, Until discontinued, Starting S |
| [] Timed voids | Every 4 hours from 6am to 10pm |
| For patients who require foley removal | Lvory + nours from oan to ropin |
| [] Foley catheter - discontinue | Routine, Once, Starting S+1 For 1 Occurrences Early AM |
| [] Straight cath | Routine, Every 4 hours, Starting S+1 |
| [] Straight cath | Early AM, after foley catheter removal start every 4 hours |

| [] Bladder scan | Routine, Every 4 hours, Starting S+1 For 3 Occurrences Initiate post-void residual early AM, after foley removal. If volume is greater than 250mL, then cath and notify attending physician |
|--|---|
| [] Timed voids | Routine, Every 4 hours, Starting S+1 Every 4 hours from 6am to 10pm |
| [] Other | , i |
| Diet / Tube Feeding / Nutrition Consults | |
| [] NPO | Diet effective now, Starting S NPO: Pre-Operative fasting options: |
| | Keep NPO until cleared by Speech |
|] Diet-Regular | Diet effective now, Starting S Diet(s): Regular Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: |
| | Foods to Avoid: |
| [] Diet-Diabetic/Cal | Diet effective now, Starting S Diet(s): Other Diabetic/Cal Diabetic/Calorie: Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: |
|] Diet-Dysphagia | Diet effective now, Starting S Diet(s): Dysphagia Solid Consistency: Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: |
|] Diet-Full liquids | Diet effective now, Starting S Diet(s): Full Liquids Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: |
|] Diet-Heart Healthy | Diet effective now, Starting S Diet(s): Heart Healthy Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: |
|] Diet-Renal | Diet effective now, Starting S Diet(s): Renal (80GM Pro, 2-3GM Na, 2-3GM K) Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: |
| Diet-Post transplant | Diet effective now, Starting S Diet(s): Post Transplant Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: |
| [] Encourage fluids | Routine, Until discontinued, Starting S |

|] Oral supplements | |
|---|--|
| | Routine Can/Bottle Supplements (8oz/240mL): |
| | Can/Bottle Supplements (8oz/240mL): |
| | Can/Bottle Supplements (8oz/240mL): |
| | Can/Bottle Supplements (8oz/240mL): |
| | Can/Bottle Supplements (8oz/240mL): |
| | Can/Bottle Supplements (8oz/240mL): |
| | Number of Cans/Bottles (8oz/240mL) each administration: |
| 1 Tube feeding | · · · · · · · · · · · · · · · · · · · |
|] Tube feeding | Diet effective now, Starting S |
| | Tube Feeding Formula: |
| | Tube Feeding Schedule: |
| | Dietitian to manage Tube Feed? |
|] Consult to Nutrition Services-MD order Diet Consult | Reason For Consult? Other (Specify),MD order Diet Consult Specify: |
|] Consult to Nutrition Services-Tube feeding | Reason For Consult? Other (Specify) |
| | Specify: Tube feeding: Initiated transition to bolus |
|] Other | The series are the se |
| Medications | |
| Nursing Medication Communication | |
| Patient may take home medications | Routine, Until discontinued, Starting S |
| • | Nurse to administer the patient approved home medications |
| Patient may not take home medications | Routine, Until discontinued, Starting S |
| 1 · anomono, not tamo nomo modicamento | Except for dietary supplements as per physician orders |
|] Swallow precautions | If patient is unable to swallow pills, call pharmacy for liquid |
| 1 Cwanow productions | form of medications |
|] Other | |
| Peripheral IV Access | |
|] Initiate and maintain IV | |
| [] Insert peripheral IV | Routine, Once |
| [] sodium chloride 0.9 % flush | 10 mL, intravenous, every 12 hours scheduled |
| [] sodium chloride 0.9 % flush | 10 mL, intravenous, PRN, line care |
| Other | 10 IIIL, IIIIavenous, Fixiv, line care |
| idocaine (XYLOCAINE) 2% jelly | |
| lidocaine (XYLOCAINE) 2 % jelly | Topical |
| Other | . op.ou |
| Anticonvulsants | |
|] LORAZepam (ATIVAN) injection | 2 mg, intravenous, once PRN, seizures, For 1 Doses |
| Other | =g,a.tooad, 01100 f 1411, 00124100, f 01 f 20000 |
| PRN Mild Pain (Pain Score 1-3) (Single Response) (adjust dose for renal/liver function and age) | |
| | |
|) acetaminophen (TYLENOL) tablet OR oral solution | "Or" Linked Panel |

| [] acetaminophen (TYLENOL) tablet | 650 mg, oral, every 6 hours PRN, mild pain (score 1-3) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Hold for sedation or respiratory depression. |
|---|---|
| [] acetaminophen (TYLENOL)suspension | 650 mg, oral, every 6 hours PRN, mild pain (score 1-3) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Use if patient cannot swallow tablet. Hold for sedation or respiratory depression. |
| [] Other | |
| PRN Oral Medications for Moderate Pain (Pain Score 4-6): F (adjust dose for renal/liver function and age) | or Patients GREATER than 65 years old (Single Response) |
| () acetaminophen-codeine (TYLENOL #3) tablet OR elixir | "Or" Linked Panel |
| Maximum of 3 grams of acetaminophen per day from all sou sources) | rces. (Cirrhosis patients maximum: 2 grams per day from all |
| [] acetaminophen-codeine (TYLENOL #3) 300-30 mg per tablet | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Give if patient is able to tolerate oral medication. |
| [] acetaminophen-codeine 300 mg-30 mg /12.5 mL solution | 12.5 mL, oral, every 6 hours PRN, moderate pain (score 4-6) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Use if patient cannot swallow tablet. |
| () HYDROcodone-acetaminophen 5/325 (NORCO) tablet OR elixir | "Or" Linked Panel |
| | rces. (Cirrhosis patients maximum: 2 grams per day from all |
| [] HYDROcodone-acetaminophen (NORCO) 5-325 mg per tablet | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6) |
| [] HYDROcodone-acetaminophen (HYCET) 2.5-108.3 mg/5 mL solution | 10 mL, oral, every 6 hours PRN, moderate pain (score 4-6) |
| () traMADol (ULTRAM) tablet - For eGFR LESS than 30 mL/min, change frequency to every 12 hours) | 25 mg, oral, every 6 hours PRN, moderate pain (score 4-6) (Max Daily dose not to exceed 200 mg/day) |
| [] Other | |
| PRN Oral Medications for Moderate Pain (Pain Score 4-6): F (adjust dose for renal/liver function and age) | or Patients LESS than 65 years old (Single Response) |
| () acetaminophen-codeine (TYLENOL #3) tablet OR elixir | "Or" Linked Panel |
| Maximum of 3 grams of acetaminophen per day from all sou sources) | rces. (Cirrhosis patients maximum: 2 grams per day from all |
| [] acetaminophen-codeine (TYLENOL #3) 300-30 mg per tablet | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Give if patient is able to tolerate oral medication. |
| [] acetaminophen-codeine 300 mg-30 mg /12.5 mL solution | 12.5 mL, oral, every 6 hours PRN, moderate pain (score 4-6) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Use if patient cannot swallow tablet. |
| () HYDROcodone-acetaminophen 5/325 (NORCO) tablet OR elixir | "Or" Linked Panel |
| | rces. (Cirrhosis patients maximum: 2 grams per day from all |

| [] HYDROcodone-acetaminophen (NORCO) 5-325 mg per tablet | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6) |
|--|--|
| [] HYDROcodone-acetaminophen (HYCET) 2.5-108.3 mg/5 mL solution | 10 mL, oral, every 6 hours PRN, moderate pain (score 4-6) |
| () HYDROcodone-acetaminophen 7.5/325 (NORCO) tablet OR elixir | "Or" Linked Panel |
| Maximum of 3 grams of acetaminophen per day from all sou sources) | rces. (Cirrhosis patients maximum: 2 grams per day from all |
| [] HYDROcodone-acetaminophen (NORCO) 7.5-325 mg per tablet | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Give if patient is able to tolerate oral medication. Hold for sedation or respiratory depression. |
| [] HYDROcodone-acetaminophen (HYCET) 7.5-325 mg/15 mL solution | 15 mL, oral, every 6 hours PRN, moderate pain (score 4-6) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Use if patient cannot swallow tablet. Hold for sedation or respiratory depression. |
| () HYDROcodone-acetaminophen 10/325 (NORCO) tablet OR elixir | "Or" Linked Panel |
| Maximum of 3 grams of acetaminophen per day from all sou sources) | rces. (Cirrhosis patients maximum: 2 grams per day from all |
| [] HYDROcodone-acetaminophen (NORCO 10-325) 10-325 mg per tablet | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Give if patient is able to tolerate oral medication. Hold for sedation or respiratory depression. |
| [] HYDROcodone-acetaminophen (HYCET) 7.5-325 mg/15 mL solution | 20 mL, oral, every 6 hours PRN, moderate pain (score 4-6) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Use if patient can not swallow tablet. Hold for sedation or respiratory depression. |
| () traMADol (ULTRAM) tablet - For eGFR LESS than 30 mL/min, change frequency to every 12 hours) | 50 mg, oral, every 6 hours PRN, moderate pain (score 4-6) (Max Daily dose not to exceed 200 mg/day) |
| Other | |
| Antiemetics | |
| X] ondansetron (ZOFRAN) IV or Oral | "Or" Linked Panel |
| [X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting Give if patient is able to tolerate oral medication. |
| [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. |
| X] promethazine (PHENERGAN) IV or Oral or Rectal | "Or" Linked Panel |
| [X] promethazine (PHENERGAN) 12.5 mg IV | 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [X] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. |
| [X] promethazine (PHENERGAN) suppository | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. |
| [] Other | |
| Antiemetics | |
| [X] ondansetron (ZOFRAN) IV or Oral | "Or" Linked Panel |
| | |

| [X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting Give if patient is able to tolerate oral medication. |
|---|--|
| [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) IV or Oral or Rectal | "Or" Linked Panel |
| [] promethazine (PHENERGAN) 12.5 mg in sodium chloride 0.9 % 0.9 % 20 mL for Alaris pump syringe option | 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. |
| [] promethazine (PHENERGAN) suppository | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. |
| [] Other | |
| Antiemetics | |
| [X] ondansetron (ZOFRAN) IV or Oral | "Or" Linked Panel |
| [X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting Give if patient is able to tolerate oral medication. |
| [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) IVPB or Oral or Rectal | "Or" Linked Panel |
| [] promethazine (PHENERGAN) 25 mg in sodium chloride 0.9 % 50 mL IVPB | 12.5 mg, intravenous, for 30 Minutes, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. |
| [] promethazine (PHENERGAN) suppository | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. |
| [] Other | |
| Scheduled Bowel Care | |
| [] docusate sodium (COLACE) capsule | 100 mg, oral, 2 times daily Hold for loose stools. |
|] senna (SENOKOT) tablet | 2 tablet, oral, daily with lunch Hold for loose stools. |
| [] polyethylene glycol (MIRALAX) packet | 17 g, oral, daily Hold for loose stools. |
| [] For Spinal Cord Patients - bisacodyl (DULCOLAX) suppository | 10 mg, rectal, daily Hold for loose stools. |
| [] Other | |
| PRN Bowel Care | |
|] bisacodyl (DULCOLAX) EC tablet | 10 mg, oral, daily PRN, constipation |
| bisacodyl (DULCOLAX) suppository | 10 mg, rectal, daily PRN, constipation |
| [] polyethylene glycol (MIRALAX) packet | 17 g, oral, 2 times daily PRN, constipation Mix in 4-8 ounces of water. |
| [] magnesium hydroxide suspension - NOT RECOMMENDED FOR CHRONIC KIDNEY DISEASE STAGE 3 OR WORSE | 30 mL, oral, every 12 hours PRN, constipation Do not give if patient is on hemodialysis or is in chronic renal failure. |
| [] sennosides-docusate sodium (SENOKOT-S) 8.6-50 mg per tablet | 2 tablet, oral, nightly PRN, constipation |
| [] docusate sodium (ENEMEEZ) enema rinted on 3/14/2019 at 3:47 PM from Production | 1 enema, rectal, nightly PRN, constipation Page 8 of 2 |
| | |

| [] Other | | |
|---|---|--|
| For Constipation still unrelieved: naloxegol (MOVANTIK) naloxegol (Movantik): For eGFR LESS than 60 mL/min or not tolerated, reduce dose to 12.5 mg once daily before breakfast on an empty stomach. Avoid use in patient with severe hepatic impairment (Child-Pugh Class C) | | |
| [] naloxegol (MOVANTIK) tablet | 25 mg, oral, daily before breakfast | |
| [] Other | | |
| Insomnia: For Patients LESS than 70 years old (Single Re | sponse) | |
| () zolpidem (AMBIEN) tablet | 5 mg, oral, nightly PRN, sleep | |
| () traZODone (DESYREL) tablet | 25 mg, oral, nightly PRN, sleep | |
| | Indication: | |
| () ramelteon (ROZEREM) tablet | 8 mg, oral, nightly PRN, sleep | |
| () mirtazapine (REMERON) tablet | 15 mg, oral, nightly PRN, sleep | |
| [] Other | Indication: | |
| [] Other | | |
| Insomnia: For Patients GREATER than or EQUAL to 70 ye | ars old (Single Response) | |
| () ramelteon (ROZEREM) tablet | 8 mg, oral, nightly PRN, sleep | |
| [] Other | | |
| Respiratory Medications | | |
| [] albuterol (PROVENTIL) nebulizer solution | 2.5 mg, nebulization | |
| | Aerosol Delivery Device: | |
| [] ipratropium (ATROVENT) 0.02 % nebulizer solution | 0.5 mg, nebulization | |
| | Aerosol Delivery Device: | |
| [] ipratropium-albuterol (DUONEB) nebulizer solution 0.5-2.5 mg/3 mL | "And" Linked Panel | |
| [] ipratropium (ATROVENT) 0.02 % nebulizer solution | 0.5 mg, nebulization, every 6 hours PRN, wheezing, shortness of breath, Wheezing Aerosol Delivery Device: | |
| [] albuterol (PROVENTIL) nebulizer solution | 2.5 mg, nebulization, every 6 hours PRN, wheezing Aerosol Delivery Device: | |
| [] acetylcysteine 200 mg/mL (20%) (MUCOMYST) | 2 mL, nebulization, every 4 hours PRN | |
| inhalation | Aerosol Delivery Device: | |
| [] Other | | |

VTE

DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

| () Low Disk of DVT | |
|---|---|
| () Low Risk of DVT [] Low Risk (Single Response) | |
| () Low risk of VTE | Routine, Once |
| () LOW HISK OF VIE | Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation |
| () Moderate Risk of DVT - Surgical | |
| Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated. | owing. Mechanical prophylaxis is optional unless |
| [] Moderate Risk | |
| [] Moderate risk of VTE | Routine, Once |
| [] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min |
| enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |

| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
|--|--|
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. |
| | weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical), Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) | |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
| () Place sequential compression device and antiembolic stockings | "And" Linked Panel |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |
| [] Place antiembolic stockings | Routine, Once |
|) Moderate Risk of DVT - Non-Surgical | |
| Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated. | owing. Mechanical prophylaxis is optional unless |
| [] Moderate Risk | |
| [] Moderate risk of VTE | Routine, Once |
| [] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once |
| | No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical) Indication: |

| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
|---|--|
| [] Mechanical Prophylaxis (Single Response) | The focus of the fact of the f |
| () Contraindications exist for mechanical prophylaxis | Routine, Once |
| () | No mechanical VTE prophylaxis due to the following |
| | contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
| () Place sequential compression device and antiembolic stockings | "And" Linked Panel |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |
| [] Place antiembolic stockings | Routine, Once |
|) High Risk of DVT - Surgical | |
| Address both pharmacologic and mechanical prophylaxis by ord | dering from Pharmacological and Mechanical Prophylaxis. |
| [] High Risk | |
| [] High risk of VTE | Routine, Once |
| [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once |
| | No pharmacologic VTE prophylaxis because: patient is |
| | already on the rapeutic anticoagulation for other indication. |
| () Contraindications exist for about a colonia prophyloxia | Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once |
| | No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | contraindication(3). |
| () enoxaparin (LOVENOX) injection (olingle Nesponse) | 40 mg, subcutaneous, daily at 0600 (time critical), Starting |
| () Ghoxapanii (20 v2 No X) Gynngg | S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL | 30 mg, subcutaneous, daily at 0600 (time critical), Starting |
| LESS than 30 mL/min | S+1 |
| | For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time |
| between 100-139 kg and CrCl GREATER than 30 | critical), Starting S+1 |
| mL/min | For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight | |
| 140 kg or GREATER and CrCl GREATER than 30 | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |
| mL/min | For Patients weight 140 kg or GREATER and CrCl |
| | GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 |
| | If the patient does not have a history or suspected case of |
| | Heparin-Induced Thrombocytopenia (HIT) do NOT order |
| | this medication. Contraindicated in patients LESS than |
| | 50kg, prior to surgery/invasive procedure, or CrCl LESS |
| | than 30 mL/min. |
| | This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 |
| | AM |
| () heparin (porcine) injection (Recommended for patients | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 |
| with high risk of bleeding, e.g. weight < 50kg and age > | AM Recommended for notionts with high risk of blooding, a g |
| 75yrs) | Recommended for patients with high risk of bleeding, e.g. |
| () warfarin (COUMADIN) tablet | weight LESS than 50kg and age GREATER than 75yrs. oral, daily at 1700 (time critical), Starting S+1 |
| | Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [1 Mechanical Prophylaxis (Single Response) | maiodioH. |

| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
|--|--|
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
| Place sequential compression device and antiembolic stockings | "And" Linked Panel |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |
| [] Place antiembolic stockings | Routine, Once |
|) High Risk of DVT - Non-Surgical | |
| Address both pharmacologic and mechanical prophylaxis by ord | dering from Pharmacological and Mechanical Prophylaxis. |
| [] High Risk | |
| [] High risk of VTE | Routine, Once |
| [] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical) Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) | |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
| () Place sequential compression device and antiembolic stockings | "And" Linked Panel |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |

| [] Place antiembolic stockings | Routine, Once |
|---|--|
| High Risk of DVT - Surgical (Hip/Knee) | |
| Address both pharmacologic and mechanical prophylaxis by or | rdering from Pharmacological and Mechanical Prophylaxis. |
| High Risk | |
| High risk of VTE | Routine, Once |
| High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () apixaban (ELIQUIS) tablet | 2.5 mg, oral, every 12 hours, Starting S+1 Indications: |
| () aspirin chewable tablet | 162 mg, oral, daily, Starting S+1 |
| () aspirin (ECOTRIN) enteric coated tablet | 162 mg, oral, daily, Starting S+1 |
| () enoxaparin (LOVENOX) injection (Single Response) | · |
| () enoxaparin (LOVENOX) syringe - hip arthoplasty | 40 mg, subcutaneous, daily at 0600 (time critical), Startin S+1 |
| () enoxaparin (LOVENOX) syringe - knee arthroplasty | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty | 30 mg, subcutaneous, daily at 0600 (time critical), Starti S+1 For Patients with CrCL LESS than 30 mL/min. |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g weight LESS than 50kg and age GREATER than 75yrs. |
| () rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission | 10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications: |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical), Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| Mechanical Prophylaxis (Single Response) | |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |

| | () | Place sequential compression device and antiembolic stockings | "And" Linked Panel | |
|---|-----|---|---------------------|--|
| | [] | Place/Maintain sequential compression device continuous | Routine, Continuous | |
| | [] | Place antiembolic stockings | Routine, Once | |
| 1 | Oth | ner | | |

DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

| () Low Risk of DVT | |
|--|--|
| [] Low Risk (Single Response) | |
| () Low risk of VTE | Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation |
| () Moderate Risk of DVT - Surgical | |
| Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated. | owing. Mechanical prophylaxis is optional unless |
| [] Moderate Risk | |
| [] Moderate risk of VTE | Routine, Once |
| [] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |

| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. |
|---|---|
| | This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical), Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| Moderate Risk of DVT - Non-Surgical | |
| Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated. | wing. Mechanical prophylaxis is optional unless |
| [] Moderate Risk [] Moderate risk of VTE | Routine, Once |
| L 3 | Routine, Once |
| [] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT orde this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical) Indication: |

| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: | | | |
|---|--|--|--|--|
| () High Risk of DVT - Surgical | mulcation. | | | |
| Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis. | | | | |
| [] High Risk | | | | |
| [] High risk of VTE | Routine, Once | | | |
| [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) | , | | | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: | | | |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): | | | |
| () enoxaparin (LOVENOX) injection (Single Response) | | | | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 | | | |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 | | | |
| | For Patients with CrCL LESS than 30 mL/min | | | |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | | | |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | | | |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): | | | |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM | | | |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. | | | |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical), Starting S+1 Indication: | | | |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: | | | |
| () High Risk of DVT - Non-Surgical | | | | |
| Address both pharmacologic and mechanical prophylaxis by ord | dering from Pharmacological and Mechanical Prophylaxis. | | | |
| [] High Risk | | | | |
| [] High risk of VTE [] High Risk Pharmacological Prophylaxis - Non-Surgical | Routine, Once | | | |
| Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation | Routine, Once | | | |
| | No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: | | | |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): | | | |

| () enoxaparin (LOVENOX) injection (Single Response) | |
|---|---|
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily, Starting S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL | 30 mg, subcutaneous, daily, Starting S+1 |
| LESS than 30 mL/min | For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 | 30 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1 |
| mL/min | For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 | 40 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical) |
| mL/min | For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily |
| | If the patient does not have a history of or suspected case |
| | of Heparin-Induced Thrombocytopenia (HIT) do NOT orde |
| | this medication. Contraindicated in patients LESS than |
| | 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. |
| | This patient has a history of or suspected case of |
| | Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () heparin (porcine) injection (Recommended for patients | 5,000 Units, subcutaneous, every 12 hours |
| with high risk of bleeding, e.g. weight < 50kg and age > | Recommended for patients with high risk of bleeding, e.g. |
| 75yrs) | weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical) Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| High Risk of DVT - Surgical (Hip/Knee) | |
| Address both pharmacologic and mechanical prophylaxis by orc | dering from Pharmacological and Mechanical Prophylaxis. |
| | |

| [] High Risk | |
|--|---|
| [] High risk of VTE | Routine, Once |
| [] High Risk Pharmacological Prophylaxis - Hip or Knee | |
| (Arthroplasty) Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once |
| | No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. |
| | Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once |
| | No pharmacologic VTE prophylaxis due to the following |
| | contraindication(s): |
| () apixaban (ELIQUIS) tablet | 2.5 mg, oral, every 12 hours, Starting S+1 |
| | Indications: |
| () aspirin chewable tablet | 162 mg, oral, daily, Starting S+1 |
| () aspirin (ECOTRIN) enteric coated tablet | 162 mg, oral, daily, Starting S+1 |
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe - hip arthoplasty | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 |
| () enoxaparin (LOVENOX) syringe - knee arthroplasty | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCl LESS than 30 mL/min - knee/hip arthroplasty | L 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 |
| | For Patients with CrCL LESS than 30 mL/min. |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |
| mL/min | For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |
| mL/min | For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |

| () | fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
|----|---|--|
| () | heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () | heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () | rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission | 10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications: |
| () | warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical), Starting S+1 Indication: |
| () | Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |

DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

| () Low Risk of DVT | |
|--|--|
| [] Low Risk (Single Response) | |
| () Low risk of VTE | Routine, Once |
| () Lett Helder VIII | Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation |
|) Moderate Risk of DVT - Surgical | |
| Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated. | owing. Mechanical prophylaxis is optional unless |
| [] Moderate Risk | |
| [] Moderate risk of VTE | Routine, Once |
| [] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |

| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
|---|---|
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 |
| () anavanaria (I O)/ENOV) auringa For Potienta weight | For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl |
| | GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 |
| | If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical), Starting S+1 |
| () Warranin (COOMADIN) tablet () Pharmacy consult to manage warfarin (COUMADIN) | Indication: STAT, Until discontinued, Starting S |
| | Indication: |
| [] Mechanical Prophylaxis (Single Response) | |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
| Place sequential compression device and antiembolic stockings | "And" Linked Panel |
| Place/Maintain sequential compression device continuous | Routine, Continuous |
| Place antiembolic stockings | Routine, Once |
| () Moderate Risk of DVT - Non-Surgical | |
| Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated. | owing. Mechanical prophylaxis is optional unless |
| [] Moderate Risk | |
| [] Moderate risk of VTE | Routine, Once |
| [] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | |

| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 1700 (time critical), Startin |
|---|--|
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 1700 (time critical), Startin |
| | For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT ord this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () heparin (porcine) injection (Recommended for patients | 5,000 Units, subcutaneous, every 12 hours |
| with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical) Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| Mechanical Prophylaxis (Single Response) | |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
| () Place sequential compression device and antiembolic stockings | "And" Linked Panel |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |
| [] Place antiembolic stockings | Routine, Once |
| High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord High Risk | |
| [] High risk of VTE | Routine, Once |
| High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600 (time critical), Startin S+1 |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600 (time critical), Startii S+1 For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| | |

| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
|---|--|
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical), Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) | |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
| () Place sequential compression device and antiembolic stockings | "And" Linked Panel |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |
| [] Place antiembolic stockings | Routine, Once |
| () High Risk of DVT - Non-Surgical | |
| Address both pharmacologic and mechanical prophylaxis by or | dering from Pharmacological and Mechanical Prophylaxis. |
| [] High Risk | |
| [] High risk of VTE | Routine, Once |
| [] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) | |
| () Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Response) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S |
| () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S For Patients with CrCL LESS than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |

| () | fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily |
|--|---|---|
| | | If the patient does not have a history of or suspected case |
| | | of Heparin-Induced Thrombocytopenia (HIT) do NOT order |
| | | this medication. Contraindicated in patients LESS than |
| | | 50kg, prior to surgery/invasive procedure, or CrCl LESS |
| | | than 30 mL/min. |
| | | This patient has a history of or suspected case of |
| | | Heparin-Induced Thrombocytopenia (HIT): |
| () | heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () | heparin (porcine) injection (Recommended for patients | 5,000 Units, subcutaneous, every 12 hours |
| | with high risk of bleeding, e.g. weight < 50kg and age > | Recommended for patients with high risk of bleeding, e.g. |
| | 75yrs) | weight LESS than 50kg and age GREATER than 75yrs. |
| () | warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical) |
| | , | Indication: |
| () | Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S |
| () | · · · · · · · · · · · · · · · · · · · | Indication: |
| [] N | Mechanical Prophylaxis (Single Response) | |
| | Contraindications exist for mechanical prophylaxis | Routine, Once |
| () | Contrainateations exist for modification propriytaxis | No mechanical VTE prophylaxis due to the following |
| | | contraindication(s): |
| <u> </u> | Place/Maintain sequential compression device | Routine, Continuous |
| () | continuous | Routine, Continuous |
| | | "And" Linked Panel |
| () | Place sequential compression device and antiembolic | And Linked Panel |
| - | stockings | Davidia a Cantinua a |
| [] | · | Routine, Continuous |
| | continuous | |
| () [] | Place antiembolic stockings | Routine, Once |
| | h Risk of DVT - Surgical (Hip/Knee) | |
| Add | dress both pharmacologic and mechanical prophylaxis by or | dering from Pharmacological and Mechanical Prophylaxis. |
| | | |
| [] H | High Risk | |
| | iigii itiak | |
| [] | High risk of VTE | Routine, Once |
| [] | | Routine, Once |
| [] [] H | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee | Routine, Once |
| [] [] H | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) | |
| [] [] H | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee | Routine, Once |
| [] [] H | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) | Routine, Once No pharmacologic VTE prophylaxis because: patient is |
| [] [] H | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. |
| [] [] () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: |
| [] [] H | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once |
| [] [] () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following |
| () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| [] [] () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 |
| () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: |
| () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 |
| () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: |
| () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 |
| () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 |
| () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 |
| () () () () () () () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 |
| () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time |
| () () () () () () () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |
| () () () () () () () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting |
| () () () () () () () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 |
| | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. |
| () () () () () () () | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty enoxaparin (LOVENOX) syringe - For Patients weight | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time |
| | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |
| | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty enoxaparin (LOVENOX) syringe - For Patients weight | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl |
| | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. |
| | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min enoxaparin (LOVENOX) syringe - For Patients weight | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time |
| | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |
| | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min enoxaparin (LOVENOX) syringe - For Patients weight | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl |
| | High risk of VTE High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 |

| () fondanarinus (ARIVTRA) injection | |
|--|--|
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission | 10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications: |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 (time critical), Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) | |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
| () Place sequential compression device and antiembolic stockings | "And" Linked Panel |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |
| [] Place antiembolic stockings | Routine, Once |
| [] Other | |
| | |
| Labs | |
| Laboratory | |
| | |
| | Once |
| Basic metabolic panel | Once Once |
| Basic metabolic panel Comprehensive metabolic panel | |
| Basic metabolic panel | Once |
| Basic metabolic panel Comprehensive metabolic panel Hepatic function panel | Once Once |
| Basic metabolic panel Comprehensive metabolic panel Hepatic function panel Fasting glucose level | Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level | Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c | Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel | Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Alkaline phosphatase | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Alkaline phosphatase [] Thyroid stimulating hormone | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Alkaline phosphatase | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Alkaline phosphatase [] Thyroid stimulating hormone | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Prealbumin level [] Tyroid stimulating hormone [] T4, free | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Prealbumin level [] Tyroid stimulating hormone [] T4, free [] Other Hematology | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Prealbumin level [] Thyroid stimulating hormone [] T4, free [] Other Hematology [] CBC with platelet and differential | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Prealbumin level [] Thyroid stimulating hormone [] T4, free [] Other Hematology [] CBC with platelet and differential [] Reticulocyte count | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Prealbumin level [] Alkaline phosphatase [] Thyroid stimulating hormone [] T4, free [] Other Hematology [] CBC with platelet and differential [] Reticulocyte count [] Prothrombin time with INR | Once Once Once Once Once Once Once Once |
| [] Basic metabolic panel [] Comprehensive metabolic panel [] Hepatic function panel [] Fasting glucose level [] Glucose level [] Hemoglobin A1c [] Lipid panel [] Phosphorus level [] Magnesium level [] Uric acid level [] Albumin level [] Prealbumin level [] Prealbumin level [] Thyroid stimulating hormone [] T4, free [] Other Hematology [] CBC with platelet and differential [] Reticulocyte count | Once Once Once Once Once Once Once Once |

| F1 - T-(-12) - 12 - P | 0 |
|---|---|
| Total iron binding capacity | Once |
| [] Ferritin level | Once |
| [] Other | |
| Microbiology | |
| | Once |
| [] Urinalysis screen and microscopy, with reflex to culture | Specimen Source: Urine |
| | Specimen Source: Office Specimen Site: |
| Urinalysis, automated with microscopy | Once |
| [] Stool culture | Once, Stool |
| [] Other | , |
| • | |
| Drug Levels | |
| [] FK506 Tacrolimus level, random | Once |
| [] Digoxin level | Once |
| [] Phenytoin level | Once |
| [] Valproic acid level | Once |
| [] Vancomycin level, random | Once |
| [] Other | |
| | |
| Cardiology | |
| Cardiology | |
| [] ECG 12 lead | Routine, Once |
| | Clinical Indications: |
| | Interpreting Physician: |
| [] Other | |
| | |
| Imaging | |
| Diagnostic Imaging | |
| XR Abdomen 1 Vw Portable | Routine, 1 time imaging For 1 |
| [] XR Chest 1 Vw Portable | Routine, 1 time imaging For 1 |
| [] XR Chest 2 Vw | Routine, 1 time imaging For 1 |
| [] XR Abdomen 2 Vw Ap W Upright And/Or Decubitus | Routine, 1 time imaging For 1 |
| US Retroperitoneal | Routine, 1 time imaging For 1 |
| Us duplex venous lower extremity | Routine, 1 time imaging |
| [] Us duplex venous upper extremity | Routine, 1 time imaging |
| Modified Barium Swallow | Routine, 1 time imaging For 1 |
| [] Other | |
| | |
| Respiratory | |
| Respiratory | |
| [] Oxygen therapy | Routine, Continuous |
| [1 Shigon morapy | Device 1: Nasal Cannula |
| | Rate in liters per minute: |
| | Rate in tenths of a liter per minute: |
| | O2 %: |
| | Device 2: |
| | Device 3: |
| | |
| | Titrate to keep O2 Sat Above: 92% |
| | Indications for O2 therapy: |
| [] BIPAP | Indications for O2 therapy: Routine, Once |
| [] BIPAP | Indications for O2 therapy: Routine, Once Mode: |
| [] BIPAP | Indications for O2 therapy: Routine, Once Mode: Resp Rate (breaths/min): |
| [] BIPAP | Indications for O2 therapy: Routine, Once Mode: Resp Rate (breaths/min): IPAP (cm H2O): |
| [] BIPAP | Indications for O2 therapy: Routine, Once Mode: Resp Rate (breaths/min): IPAP (cm H2O): EPAP (cm H2O): |
| [] BIPAP | Indications for O2 therapy: Routine, Once Mode: Resp Rate (breaths/min): IPAP (cm H2O): |

| [] CPAP | Routine, Once | |
|-----------------------------------|------------------------------------|--|
| | Bubble CPAP: | |
| | Mode: | |
| | Resp Rate (breaths/min): | |
| | CPAP (cm H2O): | |
| | O2 Bleed In (L/min): | |
| | FiO2: | |
| [] SLP passy muir valve | Routine, Once | |
| | Reason for SLP? | |
| [] Consult to Respiratory Therapy | Reason for Consult? Trach plugging | |
| [] Other | | |

Consults

Consults

If patient has a known swallowing problem or decrease level of consciousness, consult Speech-Language Pathology

| X] Consult to Case Management | Consult Reason: Discharge Planning |
|--|---|
| | For discharge planning |
| X] Consult to Social Work | Reason for Consult: Discharge Planning |
| | For discharge planning |
| X] Consult to PT eval and treat | Special Instructions: |
| | Weight Bearing Status: |
| X] Consult to OT eval and treat | Special Instructions: |
| | Weight Bearing Status: |
| X] Consult to Theraputic Recreation - Eval & Treat | Reason for Consult? Eval & Treat |
|] Consult to Speech Language Pathology | Routine, Once |
| | Reason for SLP? |
| Onsult PT wound care | Special Instructions: |
| | Location of Wound? |
|] Consult Hospitalist Medicine | Reason for Consult? |
| • | Patient/Clinical information communicated? |
| | Patient/clinical information communicated? |
|] Consult to Neuropsychology | Reason for Consult? |
| | Patient/Clinical information communicated? |
| | Patient/clinical information communicated? |
| Consult to Spiritual Care | Reason for consult? |
|] Neurologic music therapy consult - eval & treat | Routine |
| | Request Date: |
| | Please Indicate REASON FOR REFERRAL (check all that |
| | apply): |
|] Consult Ophthalmology | Reason for Consult? Functional Vision Consult |
| | Patient/Clinical information communicated? |
| [] Other | |